Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 17;25(1):23.
doi: 10.1186/s12933-026-03079-2.

Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts

Affiliations

Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts

Huangxin Zhu et al. Cardiovasc Diabetol. .

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a health issue of increasing concern worldwide. The cholesterol-high density lipoprotein-glucose (CHG) index integrates key metabolic pathways, but its relationship with the prognosis of MASLD remains unclear.

Methods: A total of 13,286 MASLD adults were included in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. The mortality results were determined by linking to the National Death Index (NDI) records. A weighted Cox model, restricted cubic spline (RCS) and threshold analysis were used to examine the nonlinear relationship between baseline CHG and all-cause (ACM) or cardiovascular mortality (CVM). Subgroup analysis examined consistency among different populations. Mediating analysis explored the mediating role of weight-adjusted waist index (WWI), neutrophil (NE) and estimated glucose disposal rate (eGDR). External validation was conducted using 2,914 individuals from the Health and Retirement Study (HRS) 2016 cohort.

Results: In a follow-up with a median time of 112 months, 1,688 cases of ACM and 551 cases of CVM occurred. Weighted Cox regression showed that an increase in the CHG index was significantly associated with an increased mortality risk in MASLD. The RCS curve and threshold effect show a significant U-shaped nonlinear relationship of the CHG index with ACM and CVM. The results of the subgroup analysis showed that the association between the CHG index and mortality risk was more significant in the subgroups under 60 years old and lean. Mediating analysis indicates that WWI, NE and eGDR may partially mediate the effects of the CHG index on ACM and CVM. In the HRS cohort, the CHG index was significantly correlated with ACM.

Conclusions: Our study confirmed a robust association between the CHG index and ACM and CVM in patients with MASLD based on the two prospective cohorts of NHANES and HRS.

Graphical abstract:

Supplementary Information: The online version contains supplementary material available at 10.1186/s12933-026-03079-2.

Keywords: Cholesterol-high density lipoprotein-glucose (CHG) index; Metabolic dysfunction-associated steatotic liver disease (MASLD); Mortality; Prospective study; Threshold effect.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The research design and implementation of NHANES follow the ethical principles outlined in the Helsinki Declaration. This study utilized data from the NHANES project that were publicly available and approved by the National Center for Health Statistics (NCHS) Ethics Review Board (ERB). NHANES requires informed consent from participants and ensures their privacy and information security. The HRS is approved by the institutional review board (IRB) of the University of Michigan, and all participants provided written informed consent. All of the data used in this study are deidentified, and most of the data are publicly available. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The flow chart of inclusion and exclusion criteria in the study
Fig. 2
Fig. 2
KM curve analysis of CHG index with ACM (A) and CVM (B) in MASLD
Fig. 3
Fig. 3
The nonlinear relationship of CHG index with ACM (A) and CVM (B) in MASLD through RCS analysis. The HR (red solid lines) and 95%CI (red shaded areas) was adjusted for gender, age, race, educational level, marital status, economic conditions, daily energy intake, smoking status, drinking status, physical activity, CVD, cancer, BMI, SBP, SUA, eGFR, LDL-C, TBIL, FIB-4 and SII
Fig. 4
Fig. 4
Each subgroup analysis was adjusted for gender, age, race, educational level, marital status, economic conditions, daily energy intake, smoking status, drinking status, physical activity, CVD, cancer, BMI, SBP, SUA, eGFR, LDL-C, TBIL, FIB-4 and SII, except for stratified variables. The threshold of p for interaction is the Bonferroni corrected α = 0.0071
Fig. 5
Fig. 5
The mediating effects of WWI (A and B), NE (C and D) and eGDR (E and F) on the relationship of CHG index with ACM and CVM in MASLD. The mediating analysis adjusted for gender, age, race, educational level, marital status, economic conditions, daily energy intake, smoking status, drinking status, physical activity, CVD, cancer, BMI, SBP, SUA, eGFR, LDL-C, TBIL, FIB-4 and SII. Abbreviations: TE: total effect; DE: direct effect; IE: indirect effect

References

    1. Younossi ZM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47. 10.1097/hep.0000000000000004. - DOI - PMC - PubMed
    1. Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–56. 10.1016/j.jhep.2023.06.003. - DOI - PubMed
    1. Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2024;80:e64–6. 10.1016/j.jhep.2023.08.021. - DOI - PubMed
    1. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:32–s50. 10.3350/cmh.2024.0431. - DOI - PMC - PubMed
    1. Schattenberg JM, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int. 2021;41:1227–42. 10.1111/liv.14825. - DOI - PMC - PubMed

LinkOut - more resources